Apex Biotechnologies Private Limited
About Apex Biotechnologies Private Limited
Data last updated:
Apex Biotechnologies Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 30 September 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U01409DL2004PTC129583.
The company has an authorised share capital of ₹2 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Ishita Wadia and Ashok Wadia.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 111 Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020.
As per the financials filed for FY 2021, the company reported a revenue of ₹14,200. For the same year it recorded a net loss of ₹20,301 (net margin -143%) and EBITDA of -₹4,411 (EBITDA margin -31.1%). Revenue has grown at a compounded annual rate (CAGR) of 53% over five years.
As per MCA filings, the company has satisfied charges of ₹3 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Apex Biotechnologies Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address111 Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020
- IndustryLife Sciences, Biotechnology
To see the full contact details of Apex Biotechnologies Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Apex Biotechnologies Private Limited
FY 2025 filings availableApex Biotechnologies Private Limited reported revenue of ₹14,200 for FY 2021.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 53% over five years. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹14,200 | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹4,411 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹20,301 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -31.1% | ||||
| Net Profit Margin | -143% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Apex Biotechnologies Private Limited, buy the company report.
Board of directors of Apex Biotechnologies Private Limited
Apex Biotechnologies has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ishita Wadia Also directs: Kanahiya Infrastructure LLP, Genesis Buildwell Private Limited, Dwarkadhish Realtors Private Limited and 5 more | Director | 11 Feb 2023 | 3 Years 8 Months | Current |
| Ashok Wadia Also directs: Spring Infrastructure LLP, Genius Urban Developers LLP, Genius Urban Developers Private Limited and 5 more | Director | 28 Jan 2022 | 4 Years 9 Months | Current |
| Gurupreet Sangla | Director | 28 Jan 2022 | 4 Years 9 Months | Current |
| Harvinder Singh | Director | 30 Sep 2004 | 22 Years 1 Months | Current |
Auditor
Apex Biotechnologies Private Limited is audited by L D SARAOGI & CO for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| L D SARAOGI & CO | FY 2018 | 005524N |
Shareholding
The shareholding of Apex Biotechnologies Private Limited is on record for 3 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Apex Biotechnologies Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Dec 2008 | 10138854 | Syndicate Bank | ₹3 Cr | Satisfied |
To see the full charge records of Apex Biotechnologies Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Apex Biotechnologies Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Apex Biotechnologies Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Apex Biotechnologies Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Apex Biotechnologies Private Limited has 8 board changes on record since 2004: 4 appointments and 4 cessations. The latest: Ishita Wadia ceased to be Additional Director on 24 Sep 2023.
1 earlier event is in the company report.
Frequently asked questions
Apex Biotechnologies is an active private limited company based in New Delhi, Delhi, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 30 September 2004 (22+ years old) and is registered under CIN U01409DL2004PTC129583.
Apex Biotechnologies has 4 current directors:
- Ishita Wadia - Director
- Ashok Wadia - Director
- Gurupreet Sangla - Director
- Harvinder Singh - Director
The latest financial statements of Apex Biotechnologies on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Apex Biotechnologies is U01409DL2004PTC129583. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Apex Biotechnologies was incorporated on 30 September 2004, making it 22+ years old. It is registered with the Registrar of Companies, Delhi.
Ishita Wadia ceased to be Additional Director on 24 Sep 2023. Ishita Wadia was appointed as Director on 11 Feb 2023. Ashok Wadia ceased to be Additional Director on 30 Sep 2022. Apex Biotechnologies has 8 board changes on record in total.
The registered office of Apex Biotechnologies is at 111 Okhla Industrial Estate Phase – III, New Delhi, Delhi, India – 110020.
Apex Biotechnologies operates in the life sciences industry, in the biotechnology segment.
Apex Biotechnologies has no open charges and satisfied charges of ₹3 Cr as per latest MCA filings.
The compliance status of Apex Biotechnologies is compliant as of 27 August 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
